Skip to main content
Shuttle Pharmaceuticals Holdings, Inc. logo

Shuttle Pharmaceuticals Holdings, Inc. — Investor Relations & Filings

Ticker · SHPH ISIN · US8256933024 US Manufacturing
Open in API
Filings indexed 266 across all filing types
Latest filing 2024-02-05 Regulatory Filings
Country US United States of America
Listing US SHPH

About Shuttle Pharmaceuticals Holdings, Inc.

https://shuttlepharma.com/

Shuttle Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company focused on developing novel therapies to improve outcomes for cancer patients. The company's mission is to enhance the effectiveness of radiation therapy (RT) by developing drugs that sensitize cancer cells to radiation while protecting adjacent healthy tissues, thereby increasing cure rates and improving quality of life. Its lead product candidate, Ropidoxuridine, is an orally available radiation sensitizer in Phase II clinical development. The pipeline also includes a portfolio of preclinical selective histone deacetylase (HDAC) inhibitors. Additionally, Shuttle is developing diagnostic technologies, including a pretreatment blood test for prostate cancer patients to help predict treatment success and inform therapeutic decisions.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2024
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. It reports a material definitive agreement entered into by the company, specifically an asset purchase agreement related to an invention. The document includes details about the agreement, consideration, and related forward-looking statements. It does not contain comprehensive financial statements or detailed financial performance data typical of annual or quarterly reports. It is not an earnings release, proxy statement, or other specialized filing. The Form 8-K is a regulatory filing used to report significant events and is classified under Regulatory Filings (RNS) as it does not fit into more specific categories like Annual Report, Interim Report, or Capital Update. The document length (7648 characters) and content confirm it is a full Form 8-K report, not just an announcement of a report publication or certification.
2024-02-05 English
Regulatory Filings 2024
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text includes a press release about receiving a 'Safe to Proceed' letter from the FDA for a Phase II study, which is an event update rather than a financial report. The document explicitly states it is a 'Current Report' and includes no financial statements or detailed financial analysis. It also references the press release as Exhibit 99.1, indicating the main content is an event announcement. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2024-01-08 English
Director's Dealing 2024
Director's Dealing
2024-01-02 English
Director's Dealing 2023
Director's Dealing
2023-12-21 English
Declaration of Voting Results & Voting Rights Announcements 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated December 18, 2023, reporting the results of the company's annual meeting of shareholders. It details the voting outcomes for the election of directors, ratification of independent auditors, and approval of executive compensation. The key focus is on the submission of matters to a vote of security holders and the official voting results. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). The document length is 4258 characters, which is consistent with a detailed voting results announcement rather than a brief report publication or a full annual report. Therefore, the correct classification is DVA with high confidence.
2023-12-19 English
Regulatory Filings 2023
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text includes a press release about the submission of an Investigational New Drug application, which is a regulatory disclosure event. The document is short (4073 characters) and primarily furnishes a press release rather than detailed financial data or comprehensive reports. It does not contain financial statements or detailed management discussion. Therefore, it is not an Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). It is a regulatory announcement of a material event, fitting the category of Regulatory Filings (RNS).
2023-12-11 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.